Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia - a pivotal double-blind, cross-over controlled study

Roberto W. Dal Negro; Paola Turco; Massimiliano Povero

doi:10.4081/mrm.2022.886

Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia - a pivotal double-blind, cross-over controlled study

Authors

Roberto W. Dal Negro National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology - CESFAR, Verona https://orcid.org/0000-0001-6305-0732
Paola Turco Research & Clinical Governance, Verona
Massimiliano Povero AdRes Health Economics and Outcome Research, Turin https://orcid.org/0000-0003-0666-066X

DOI: https://doi.org/10.4081/mrm.2022.886

Keywords:

Nebivolol, COVID-19, vascular effects, lung perfusion, capillary blood volume (Vc), simultaneous DLCO and DLNO assessment

Abstract

Background: Pulmonary microvascular occlusions can aggravate SARS-CoV-2 pneumonia and result in a variable decrease in capillary blood volume (Vc). Dyspnoea may persist for several weeks after hospital discharge in many patients who have "radiologically recovered" from COVID-19 pneumonia. Dyspnoea is frequently "unexplained" in these cases because abnormalities in lung vasculature are understudied. Furthermore, even when they are identified, therapeutic options are still lacking in clinical practice, with nitric oxide (NO) supplementation being used only for severe respiratory failure in the hospital setting. Nebivolol is the only selective β₁ adrenoceptor antagonist capable of inducing nitric oxide-mediated vasodilation by stimulating endothelial NO synthase via β₃ agonism. The purpose of this study was to compare the effect of nebivolol versus placebo in patients who had low Vc and complained of dyspnoea for several weeks after COVID-19 pneumonia.
Methods: Patients of both genders, aged ≥18 years, non-smokers, who had a CT scan that revealed no COVID-related parenchymal lesions but still complained of dyspnoea 12-16 weeks after hospital discharge, were recruited. Spirometrical volumes, blood haemoglobin, SpO₂, simultaneous diffusing capacity for carbon monoxide (CO) and NO (DL_CO and DL_NO, respectively), DL_NO/DL_CO ratio, Vc and exhaled NO (eNO) were measured together with their dyspnoea score (DS), heart frequency (HF), and blood arterial pressure (BAP). Data were collected before and one week after both phosphorus (P) and nitrogen (N) (2.5 mg od) double-blind cross-over administered at a two-week interval. Data were statistically compared, and p<0.05 assumed as statistically significant.
Results: Eight patients (3 males) were investigated. In baseline, their mean DS was 2.5±0.6 sd, despite the normality of lung volumes. DL_CO and DL_NO mean values were lower than predicted, while mean DL_NO/DL_CO ratio was higher. Mean Vc proved substantially reduced. Placebo did not modify any variable (all p=ns) while N improved DL_CO and Vc significantly (+8.5%, p<0.04 and +17.7%, p<0.003, respectively). Also eNO was significantly increased (+17.6%, p<0.002). Only N lowered the dyspnoea score (-76%, p<0.001). Systolic and diastolic BAP were slightly lowered (-7.5%, p< 0.02 and -5.1% p< 0.04, respectively), together with HF (-16.8%, p<0.03).
Conclusions: The simultaneous assessment of DL_NO, DL_CO, DL_NO/DL_CO ratio, and Vc confirmed that long-lasting dyspnoea is related to hidden abnormalities in the lung capillary vasculature. These abnormalities can persist even after the complete resolution of parenchymal lesions regardless of the normality of lung volumes. Nebivolol, but not placebo, improves DS and Vc significantly. The mechanism suggested is the NO-mediated vasodilation via the β₃ adrenoceptor stimulation of endothelial NO synthase. This hypothesis is supported by the substantial increase of eNO only assessed after nebivolol. As the nebivolol tolerability in these post-COVID normotensive patients was very good, the therapeutic use of nebivolol against residual and symptomatic signs of long-COVID can be suggested in out-patients.

References

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33.

Matricardi PM, Dal Negro RW, Nisini R. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol 2020;31:454-70.

Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536-44.

Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, et al. Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019. medRxiv 2020.03.05.20030502.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.

Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

Okba NMA, Müller MA, Li W, Wang C, Geurtsvan Kessel CH, Corman VM, et al. Severe acute respiratory syndrome coronavirus 2−specific antibody responses in coronavirus disease patients. Emerg Infect Dis 2020;26:1478-88.

El Karoui K, Hill GS, Karras A, Jacquot C, Moulonguet L, Kourilsky O, et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 2012;23:137-48.

Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Med Pathol 2020;33:1007-14.

Orwoll BE, Spicer AC, Zinter MS, Alkhouli MF, Khemani RG, Flori HR, et al. Elevated soluble thrombomodulin is associated with organ failure and mortality in children with acute respiratory distress syndrome (ARDS): a prospective observational cohort study. Crit Care 2015;19:435.

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844-7.

Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost 2020;18:1752-5.

Hughes JMB, Pride NB. Examination of the carbon monoxide diffusing capacity (DLCO) in relation to its KCO and VA components. Am J Respr. Crit Care Med 2012;186:132–9.

Wu X, Lin X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-month, 6-month. 9-month. And 12-month respiratory outcomes in patients following COVID-19 related hospitalization: a prospective study. Lancet Respir Med 2021;9:747-54.

Frija-Masson J, Debray M-P, Gilbert M, Lescure FX, Travert F, Borie R, et al. Functional characteristics of patients with SARS-CoV- 2 pneumonia at 30 days post-infection. Eur Resp J 2020;56:2001754.

Mo X, Jian W, Su Z, Chen MU, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 2020;55:2001217.

Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res 2020;1:163.

van den Borst B, Peters JB, Brink M, Schoon Y, Bleeker-Rovers CP, Schers H, et al. Comprehensive health assessment three months after recovery from acute COVID-19. Clin Infect Dis 2021;73:e1089-98.

Guenard H, Varene N, Vaida P. Determination of lung capillary blood volume and membrane diffusing capacity by measurement of NO and CO transfer. Resp Physiol 1987;70,113–20.

Borland CDR, Hughes JMB. Lung diffusing capacities (DL) for nitric oxide (NO) and carbon monoxide (CO): The evolving story. Compr Physiol 2019;10:73–97.

Gibson QH, Roughton FJW. The kinetics and equilibria of the reactions of nitric oxide with sheep haemoglobin. J Physiol 1957;136:507-24.

Barisone G, Brusasco V. Lung diffusing capacity for nitric oxide and carbon monoxide following mild-to-severe COVID-19. Physiol Rep2021;9:e14748.

Borland CD, Dunningham H, Bottrill F, Vuylsteke A, Yilmaz C, Dane DM, et al. Significant blood resistance to nitric oxide transfer in the lung. J Appl Physiol 1985;108:1052-60.

Zavorsky GS, Hsia CCW, Hughes JMB, Borland CDR, Guénard H, van der Lee I, et al. Standardisation and application of the single-breath determination of nitric oxide uptake in the lung. Eur Respir J 2017;49:1600962.

Roughton FJ, Forster RE. Relative importance of diffusion and chemical reaction in determining rate of exchange of gases in the human lung. J Appl Physiol 1957;11:290-302.

Dal Negro RW, Turco P, Povero M. Long-lasting dyspnoea in patients otherwise clinically and radiologically recovered from COVID pneumonia: a probe for checking persisting disorders in capillary lung volume as a cause. Multidiscip Respir Med 2022;17:875.

Rossaint R, Gerlach H, Schmidt-Ruhnke H, Pappert D, Lewandowski K, Steudel W, et al. – Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 1995;107:1107-15.

Ichinose F, Roberts JD, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: currents uses and therapeutic potential. Circulation 2004;109:3106-11.

Bristow M, Nelson P, Minobe W, Johnson C. Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium. Am J Hypertens 2005;18;51A-52A.

Pedersen ME, Cockroft J. The vasodilatory beta-blockers. Curr Hypertens Rep 2007;9:269-77.

Munzel T, Gori T. Nebivolol: the somewhat different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009;54:1491-9.

Fongemie J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs 2015;75:1349-71.

Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, et al. ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J 2017;49:1600016.

Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnoea. Chest 1988;93:580-6.

Ignarro IJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002;90:21-8.

Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroideal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002;137:295-310.

Scatena R, Bottoni P, Martorana GE, Giardina B. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs 2005;14:835-46.

Mason RP, Cockroft JR. Targeting nitric oxide with drug therapy. J Clin Hypert 2006;8:40-52.

Kalinowski I, Dobrocki LW, Szczepanska-Konkel M, Konkel M, Jankowski M, Martyniec L, et al. Third-generation β-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003;107:2747-514.

Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, cross-over study. Circulation 2001;104:511-14.

Ritter JM. Nebivolol: endothelium-mediasted vasodilating effect. J Cardiovasc Pharmacol 2001;38:s13-6.

Mollnau H, Schulz E, Daiber A, Baldus S, Oelze M, August M, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003;23:615-21.

Tang H, Vanderpool RR, Wang J, Yuan JX. Targeting L-arginine-nitric oxide-cGMP pathway in pulmonary arterial hypertension. Pulm Circul 2017;7:569-71.

Garcia-Alvarez A, Pereda D, Garcia-Lunar I, Sanz-Rosa A, Fernandez-Jimenez R, Garcia-Prito J, et al. Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension. Basic Res Cardiol 2016;111:49.